Extracellular Vesicle-mediated Suicide MRNA/protein Delivery Inhibits Glioblastoma Tumor Growth in Vivo

Overview

Journal Cancer Gene Ther

Specialties Genetics
Oncology
Pharmacology

Date 2016 Dec 17

PMID 27982017

Citations 20

Authors

E P Erkan

D Senfter

S Madlener

G Jungwirth

T Strobel

N Saydam

O Saydam

Affiliations

Soon will be listed here.

Abstract

Extracellular vesicles (EVs) are considered as important mediators of intercellular communication, which carry a diverse repertoire of genetic information between cells. This feature of EVs can be used and improved to advance their therapeutic potential. We have previously shown that genetically engineered EVs carrying the suicide gene mRNA and protein-cytosine deaminase (CD) fused to uracil phosphoribosyltransferase (UPRT)-inhibited schwannoma tumor growth in vivo. To further examine whether this approach can be applied to other cancer types, we established a subcutaneous xenograft glioblastoma tumor model in mice, as glioblastoma represents the most common primary brain tumor, which is highly aggressive compared with the original schwannoma tumor model. U87-MG glioblastoma cells were implanted into the flanks of nude SCID mice, and the animals were intratumorally injected with the EVs isolated from the cells expressing EGFP or CD-UPRT. After the intraperitoneal administration of the prodrug 5-fluorocytosine, the tumor growth was assessed by regular caliper measurements. Our data revealed that the treatment with the CD-UPRT-enriched EVs significantly reduced the tumor growth in mice. Taken together, our findings suggest that EVs uploaded with therapeutic CD-UPRT mRNA/protein may be a useful tool for glioblastoma treatment.

Citing Articles

Exosomes: from basic research to clinical diagnostic and therapeutic applications in cancer.

Araujo-Abad S, Berna J, Lloret-Lopez E, Lopez-Cortes A, Saceda M, de Juan Romero C Cell Oncol (Dordr). 2024; .

PMID: 39298081 DOI: 10.1007/s13402-024-00990-2.

How to Develop Drug Delivery System Based on Carbohydrate Nanoparticles Targeted to Brain Tumors.

Silantev V, Shmelev M, Belousov A, Patlay A, Shatilov R, Farniev V Polymers (Basel). 2023; 15(11).

PMID: 37299315 PMC: 10255125. DOI: 10.3390/polym15112516.

Suicide gene strategies applied in ovarian cancer studies.

Nguyen Q, Dupre P, Haute T, Montier T, dArbonneau F Cancer Gene Ther. 2023; 30(6):812-821.

PMID: 36717737 DOI: 10.1038/s41417-023-00590-6.

Preclinical and Clinical Applications of Metabolomics and Proteomics in Glioblastoma Research.

Ahmed M, Semreen A, El-Huneidi W, Bustanji Y, Abu-Gharbieh E, Alqudah M Int J Mol Sci. 2023; 24(1).

PMID: 36613792 PMC: 9820403. DOI: 10.3390/ijms24010348.

Advances of engineered extracellular vesicles-based therapeutics strategy.

Komuro H, Aminova S, Lauro K, Harada M Sci Technol Adv Mater. 2022; 23(1):655-681.

PMID: 36277506 PMC: 9586594. DOI: 10.1080/14686996.2022.2133342.

References

Huber B, Austin E, Richards C, Davis S, Good S . Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A. 1994; 91(17):8302-6. PMC: 44594. DOI: 10.1073/pnas.91.17.8302. View

Mizrak A, Bolukbasi M, Ozdener G, Brenner G, Madlener S, Erkan E . Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Mol Ther. 2012; 21(1):101-8. PMC: 3538300. DOI: 10.1038/mt.2012.161. View

Fleury A, Martinez M, Le Lay S . Extracellular vesicles as therapeutic tools in cardiovascular diseases. Front Immunol. 2014; 5:370. PMC: 4120684. DOI: 10.3389/fimmu.2014.00370. View

Bolukbasi M, Mizrak A, Ozdener G, Madlener S, Strobel T, Erkan E . miR-1289 and "Zipcode"-like Sequence Enrich mRNAs in Microvesicles. Mol Ther Nucleic Acids. 2013; 1:e10. PMC: 3381601. DOI: 10.1038/mtna.2011.2. View

Noerholm M, Balaj L, Limperg T, Salehi A, Zhu L, Hochberg F . RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer. 2012; 12:22. PMC: 3329625. DOI: 10.1186/1471-2407-12-22. View

Kaliberov S, Chiz S, Kaliberova L, Krendelchtchikova V, Della Manna D, Zhou T . Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity. Cancer Gene Ther. 2005; 13(2):203-14. DOI: 10.1038/sj.cgt.7700874. View

Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N . Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2012; 21(1):185-91. PMC: 3538304. DOI: 10.1038/mt.2012.180. View

Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F . In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 2000; 60(14):3813-22. View

Pizzirani C, Ferrari D, Chiozzi P, Adinolfi E, Sandona D, Savaglio E . Stimulation of P2 receptors causes release of IL-1beta-loaded microvesicles from human dendritic cells. Blood. 2006; 109(9):3856-64. DOI: 10.1182/blood-2005-06-031377. View

10.

Chen M, Green N, Burton A, Anderson D, Mautner V, Searle P . In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther. 2001; 8(20):1547-54. DOI: 10.1038/sj.gt.3301557. View

11.

Adachi Y, Tamiya T, Ichikawa T, Terada K, Ono Y, Matsumoto K . Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Hum Gene Ther. 2000; 11(1):77-89. DOI: 10.1089/10430340050016175. View

12.

Waldenstrom A, Genneback N, Hellman U, Ronquist G . Cardiomyocyte microvesicles contain DNA/RNA and convey biological messages to target cells. PLoS One. 2012; 7(4):e34653. PMC: 3323564. DOI: 10.1371/journal.pone.0034653. View

13.

Balaj L, Lessard R, Dai L, Cho Y, Pomeroy S, Breakefield X . Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun. 2011; 2:180. PMC: 3040683. DOI: 10.1038/ncomms1180. View

14.

Omuro A, DeAngelis L . Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013; 310(17):1842-50. DOI: 10.1001/jama.2013.280319. View

15.

Bianco F, Pravettoni E, Colombo A, Schenk U, Moller T, Matteoli M . Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. J Immunol. 2005; 174(11):7268-77. DOI: 10.4049/jimmunol.174.11.7268. View

16.

Boucher P, Im M, Freytag S, Shewach D . A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res. 2006; 66(6):3230-7. DOI: 10.1158/0008-5472.CAN-05-3033. View

17.

Ho W, Yeap S, Ho C, Rahim R, Alitheen N . Development of multicellular tumor spheroid (MCTS) culture from breast cancer cell and a high throughput screening method using the MTT assay. PLoS One. 2012; 7(9):e44640. PMC: 3435305. DOI: 10.1371/journal.pone.0044640. View

18.

Ridder K, Keller S, Dams M, Rupp A, Schlaudraff J, Del Turco D . Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation. PLoS Biol. 2014; 12(6):e1001874. PMC: 4043485. DOI: 10.1371/journal.pbio.1001874. View

19.

Erkan E, Strobel T, Lewandrowski G, Tannous B, Madlener S, Czech T . Depletion of minichromosome maintenance protein 7 inhibits glioblastoma multiforme tumor growth in vivo. Oncogene. 2013; 33(39):4778-85. DOI: 10.1038/onc.2013.423. View

20.

Cloughesy T, Cavenee W, Mischel P . Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol. 2013; 9:1-25. DOI: 10.1146/annurev-pathol-011110-130324. View